FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362593663> ?p ?o ?g. }

• W4362593663 endingPage "768" @default.
• W4362593663 startingPage "768" @default.
• W4362593663 abstract "Abstract Background: Bladder cancer (BC) is one of the most common cancers worldwide. Muscle invasion BC (MIBC) has a poor prognosis and is usually in an advanced stage. Recently, whole genome sequencing research in BC has pointed out the molecular subtypes of BC which presented correlate with the patient outcome as well as clinical behavior. There are differences between the stratification’s subtypes determined by several research teams. However, the central of these stratifications are classified the BC into the basal BC type and the luminal BC type. We aim to use the immunohistochemical surrogated markers for basal and luminal BC subtypes to discriminate the molecular subtypes of BC and their association with the clinicopathologic features of BC. Method: We performed IHCs for surrogated basal makers (CK5/6 and CD44), and surrogated luminal makers (CK20 and Gata3) in 130 MIBC patients. IHCs classified the MICB into the fourth group including basal type (positive with CK5/6 and/or CD44 and negative both of CK20 and Gata3), luminal type (negative both of CK5/6 and CD44 and positive with CK20 and/or Gata3), null type (negative for all fourth markers) and mixed type (expressed both basal and luminal markers), respectively. We investigated the relationship between the molecular subtypes and the clinicopathological significance of MIBC patients. Furthermore, we analyzed the association of molecular subtypes with the overall survival of MIBC patients. We also analyzed the IMVigor210 cohort and the TCGA-BLCA cohort to validate our results. We investigated the chemo reagents (cisplatin, and 5-Fu) resistance of the BC cell lines which molecular subtypes classified by IHCs. Results: We figured out that the basal subtype and luminal subtype presented 35.28% and 29.23% of MIBC respectively. The null subtype accounted for 18.47% of MIBC. The basal subtype was associated with T stage (p=0.035), squamous differentiation (p=0.0002), stage (p=0.035), and tumor infiltrated lymphocytes (TILs) (p=0.047). There were no significantly different between the overall survival of the basal and mixed subtype of MIBC and the luminal and null subtype MIBC (Log-rank test, p=0.090). Interestingly, we explored that the MIBC without intensive TILs - basal subtype presented the worst prognosis in comparison with other molecular subtypes (Log-rank test, p=0.012). The mRNA basal subtype also presented poor prognosis in BC without immune activities in BLCA (p=0.037) or in IMVigor210 (p=0.0005). Furthermore, the basal cell lines presented lower IC50 than luminal cell lines when treated the cells with cisplatin. Conclusion: Our results pointed out that the molecular subtypes of MIBC were associated with the progression of MIBC. The MIBC patients without intensive TILs - basal subtype have the worst outcome. Suggesting that stratification of molecular subtypes of MIBC by IHCs are appealing option for clinical implementation. Citation Format: QuocThang Pham, Anh Toan Do, Ngoc Minh Tam Nguyen, Phuc Nguyen Nguyen, Thi Phuong Thao Doan, Thi Thanh Tam Bui, Quoc Dat Ngo. Immunohistochemistry analysis of the molecular subtypes of muscle invasive bladder cancer in association with prognosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 768." @default.
• W4362593663 created "2023-04-06" @default.
• W4362593663 creator A5016542608 @default.
• W4362593663 creator A5018163917 @default.
• W4362593663 creator A5020489299 @default.
• W4362593663 creator A5030959574 @default.
• W4362593663 creator A5068136887 @default.
• W4362593663 creator A5086431905 @default.
• W4362593663 creator A5087343995 @default.
• W4362593663 date "2023-04-04" @default.
• W4362593663 modified "2023-10-16" @default.
• W4362593663 title "Abstract 768: Immunohistochemistry analysis of the molecular subtypes of muscle invasive bladder cancer in association with prognosis" @default.
• W4362593663 doi "https://doi.org/10.1158/1538-7445.am2023-768" @default.
• W4362593663 hasPublicationYear "2023" @default.
• W4362593663 type Work @default.
• W4362593663 citedByCount "0" @default.
• W4362593663 crossrefType "journal-article" @default.
• W4362593663 hasAuthorship W4362593663A5016542608 @default.
• W4362593663 hasAuthorship W4362593663A5018163917 @default.
• W4362593663 hasAuthorship W4362593663A5020489299 @default.
• W4362593663 hasAuthorship W4362593663A5030959574 @default.
• W4362593663 hasAuthorship W4362593663A5068136887 @default.
• W4362593663 hasAuthorship W4362593663A5086431905 @default.
• W4362593663 hasAuthorship W4362593663A5087343995 @default.
• W4362593663 hasConcept C102037460 @default.
• W4362593663 hasConcept C104317684 @default.
• W4362593663 hasConcept C121608353 @default.
• W4362593663 hasConcept C126322002 @default.
• W4362593663 hasConcept C142724271 @default.
• W4362593663 hasConcept C143998085 @default.
• W4362593663 hasConcept C204232928 @default.
• W4362593663 hasConcept C2778024521 @default.
• W4362593663 hasConcept C2779306644 @default.
• W4362593663 hasConcept C2780352672 @default.
• W4362593663 hasConcept C54355233 @default.
• W4362593663 hasConcept C71924100 @default.
• W4362593663 hasConcept C72563966 @default.
• W4362593663 hasConcept C86339819 @default.
• W4362593663 hasConcept C86803240 @default.
• W4362593663 hasConceptScore W4362593663C102037460 @default.
• W4362593663 hasConceptScore W4362593663C104317684 @default.
• W4362593663 hasConceptScore W4362593663C121608353 @default.
• W4362593663 hasConceptScore W4362593663C126322002 @default.
• W4362593663 hasConceptScore W4362593663C142724271 @default.
• W4362593663 hasConceptScore W4362593663C143998085 @default.
• W4362593663 hasConceptScore W4362593663C204232928 @default.
• W4362593663 hasConceptScore W4362593663C2778024521 @default.
• W4362593663 hasConceptScore W4362593663C2779306644 @default.
• W4362593663 hasConceptScore W4362593663C2780352672 @default.
• W4362593663 hasConceptScore W4362593663C54355233 @default.
• W4362593663 hasConceptScore W4362593663C71924100 @default.
• W4362593663 hasConceptScore W4362593663C72563966 @default.
• W4362593663 hasConceptScore W4362593663C86339819 @default.
• W4362593663 hasConceptScore W4362593663C86803240 @default.
• W4362593663 hasIssue "7_Supplement" @default.
• W4362593663 hasLocation W43625936631 @default.
• W4362593663 hasOpenAccess W4362593663 @default.
• W4362593663 hasPrimaryLocation W43625936631 @default.
• W4362593663 hasRelatedWork W1625389978 @default.
• W4362593663 hasRelatedWork W1979321249 @default.
• W4362593663 hasRelatedWork W202920663 @default.
• W4362593663 hasRelatedWork W2077325982 @default.
• W4362593663 hasRelatedWork W2125713350 @default.
• W4362593663 hasRelatedWork W2315085516 @default.
• W4362593663 hasRelatedWork W2474195589 @default.
• W4362593663 hasRelatedWork W2603773853 @default.
• W4362593663 hasRelatedWork W3138581044 @default.
• W4362593663 hasRelatedWork W2118673085 @default.
• W4362593663 hasVolume "83" @default.
• W4362593663 isParatext "false" @default.
• W4362593663 isRetracted "false" @default.
• W4362593663 workType "article" @default.